Podcast appearances and mentions of Paul Volberding

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Paul Volberding from the University of California San Francisco about long COVID and new long COVID disability guidelines. They discuss the symptoms and causes of long COVID and where to find treatment. Dr Volberding discussed his work with the National Academy of Medicine, which recently released a report on long COVID disability guidelines. 0:00 – Introduction1:53 – What is long COVID? How does someone know if they have it? 6:22 – Risk factors and causes of long COVID11:51 – Treatments for and research on long COVID 14:14 – When is long COVID a disability? Disability recommendations from the National Academy of Medicine on long COVID19:53 – How does someone with long COVID get help?23:54 - Closing Remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Episode 3 - Latest Update on Emerging and Reemerging Urgent Viral Outbreaks, Including COVID-19, MPOX, and Flu. October 2023  In today's episode of Going anti-Viral, we present a recent dialogue from October 19th, 2023, with special guest Katelyn K. Jetelina, MPH, PhD. Dr Jetelina is an epidemiologist, data scientist, and author of the popular newsletter "Your Local Epidemiologist (YLE)". She joined moderator Paul Volberding, MD, and discussants Peter Chin-Hong, MD, and Carlos del Rio, MD, for a lively discussion on the latest hot-button issues in the field of infectious diseases.Key conversations focus on the state of the COVID-19 pandemic, the role of vaccines and the growing issues related to insufficient data when tracking and treating viral infections. The discussion further extends to examine the political backlash that threatens institutional trust, pushing for a stronger approach that involves community-based contributions to conquering infectious diseases.00:08 Introduction and Guest Presentation01:16 Guest Introductions and Backgrounds04:48 Discussion on Current Infectious Disease Trends09:14 The Role of Data in Tracking Disease Trends12:30 The Politics of Public Health Data16:41 The Impact of Politics on Vaccination16:54 Vaccination Discussion: COVID-19, Influenza, and RSV26:20 Influenza Season Discussion28:24 Discussion on Vaccination Coverage and Data Collection30:30 The Importance of Vaccination Timing and Convenience31:33 Understanding RSV in Adults and Its Diagnosis32:28 The Importance of Testing and the Impact of COVID-19 on Testing Practices33:13 The Challenge of Distinguishing Between Different Respiratory Infections34:27 Discussion on Influenza Vaccines and Their Effectiveness36:08 The Importance of Vaccination and Addressing Vaccine Hesitancy43:55 The Future of Vaccines09:10 Addressing the Challenges of Misinformation and Trust in Public Health__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

San Francisco is often thought of as the birthplace of advocacy and innovation in combating the HIV epidemic. In this episode, Shieva and Nicole are joined by the world-renowned physician and researcher, Dr. Paul Volberding. Dr. Volberding not only took care of one of the first patients with HIV in the country, but he also was the co-founder of Ward 86, the world's first HIV/AIDs specialty clinic. Dr. Volberding shares his insights and experiences from the harrowing early days of the deadly HIV epidemic. He discusses the vital roles of nurses, volunteers, and the San Francisco community as advocates for resources and research to be directed into supporting this largely marginalized community. Join us for this meaningful dialogue about the pioneer days of HIV care in San Francisco.   Articles discussed: https://www.who.int/news-room/spotlight/why-the-hiv-epidemic-is-not-over Life Before the Lifeboat Documentary: https://youtu.be/rOauL9VDpSk To learn more about Dr. Paul Volberding: https://medconnection.ucsfhealth.org/participant/paul-volberding-md

Han är en av få överlevande som smittades i den tidiga hiv-epidemin i Kalifornien på 80-talet, och liksom andra veteraner lider han både fysiskt och psykiskt idag. I San Francisco finns världens främsta center för att hjälpa överlevarna. "Det finns inget vi kan göra, sa läkarna, och skickade mig i princip hem för att dö", säger Sergio Flores, som var 29 år när han smittades av hiv 1986. Men till skillnad från många av hans vänner överlevde han, till stor del tack vare bromsmedicinerna som kom 10 år senare.Liksom andra långtidsöverlevare som vi möter i Vetenskapsradion På djupet bär han på svåra minnen och även skuldkänslor för att just han klarat sig. Många lider av depression och PTSD, och deras kroppar har åldrats i förtid så att de nu ses som patienter för geriatriken, alltså vård av äldre.Vi besöker avdelning 86 på San Francisco general hospital, som tidigt blev specialiserad på vård av hiv-patienter, och där nästan alla dog i början. Men efterhand lärde sig läkarna att det fanns saker att göra, och idag är det den främsta mottagningen i världen för vård och stöd till överlevarna.Medverkande: Sergio Flores, Michael Rouppet och Paul Aguilar, hiv-överlevare i San Francisco; Meredith Greene, biträdande professor i geriatrik vid universitetet UCSF och specialiserad på åldrande bland hiv-positiva; Paul Volberding, läkare på San Francisco General Hospital som arbetat på hiv-mottagningen sedan 80-talet och som var med och grundade världens första aidsklinik.Reporter: Lena Nordlund lena.nordlund@sr.seProducent: Björn Gunér bjorn.guner@sr.se

In this episode, host Dr Michael Saag speaks with Dr Paul Volberding, founder of the world's first dedicated HIV outpatient clinic, about their clinical experience treating HIV from the early days of the pandemic until now. They discuss the medical breakthroughs that they have seen over the years and how the history of HIV treatment directly informs treatment today. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963236). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources Kaposi sarcoma clinical presentation https://emedicine.medscape.com/article/279734-clinical Lymphadenopathy: endpoint or prodrome? Update of a 24-month prospective study https://pubmed.ncbi.nlm.nih.gov/6335951/ Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) https://pubmed.ncbi.nlm.nih.gov/6189183/ The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial https://pubmed.ncbi.nlm.nih.gov/3299089/ The history of PCR http://siarchives.si.edu/research/videohistory_catalog9577.html History of HAART -- the true story of how effective multi-drug therapy was developed for treatment of HIV disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1716971/

World renowned HIV/AIDS researcher Dr. Paul Volberding told us last year that COVD-19 vaccine research had set back the cure for AIDS because many AIDS researchers were pulled away to work on COVID-19. Now that there’s a COVID-19 vaccine rollout, DIFFA/Dallas is revisiting the question: How close are we to a cure for HIV/AIDS?

In the third episode to honor World AIDS Day, on the 1st December, we are discussing the U=U message with Professor Paul Volberding, University of California San Francisco. We touch on the recently published multicentre study: Undetectable equals untransmittable (U = U): awareness and associations with health outcomes among people living with HIV in 25 countries discuss by Okoli et al. Read the open-access paper on the Sexually Transmitted Infections website: http://dx.doi.org/10.1136/sextrans-2020-054551 . Please subscribe to the STI podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify to get the latest episode onto your device.

Episode 24 of IMPACT features Dr. Paul Volberding, a global pioneer in HIV/AIDS research and treatment. Dr. Volberding is the Director of the UCSF AIDS Research Institute and Founding Chair of the Board of the International Antiviral Society. He was also involved in the first clinical trials for antiretroviral therapy, and established the world's first outpatient clinic for people with AIDS back in 1983. Dr. Volberding and host Shane Allen talk about the big question: How close are we to a cure for HIV and AIDS?

As part of the Red Journal’s special issue focused on COVID-19 and its impact on Radiation Oncology, the October 2020 Issue Highlights podcast has been produced in conjunction with the Virtual Visiting Professor Network. The podcast is hosted by Editor-in-Chief Anthony Zietman, MD, FASTRO and Deputy Editor Sue Yom, MD, PhD, and features guests Paul Volberding, MD, and Daphne Haas-Kogan, MD. Drs. Volberding and Haas-Kogan share their stories of working with patients with HIV, and reflect upon parallels to today's COVID-19 pandemic.

As part of the Red Journal’s special issue focused on COVID-19 and its impact on Radiation Oncology, the October 2020 Issue Highlights podcast has been produced in conjunction with the Virtual Visiting Professor Network. The podcast is hosted by Editor-in-Chief Anthony Zietman, MD, FASTRO and Deputy Editor Sue Yom, MD, PhD, and features guests Paul Volberding, MD, and Daphne Haas-Kogan, MD. Drs. Volberding and Haas-Kogan share their stories of working with patients with HIV, and reflect upon parallels to today's COVID-19 pandemic.

Dr. Paul Volberding of The University of California San Francisco and Dr. Fay Hlubock, a clinical health psychologist from The University of Chicago, join us for a discussion on mental health. We talk about the toll the COVID-19 pandemic has taken on the mental health of healthcare professionals and what can be done to reverse this, while increasing resiliency.

In this episode, we talk to one of the founding doctors of Ward 86, the first dedicated HIV/AIDS clinic in the nation. UC San Francisco oncologist Paul Volberding describes how he and his colleagues pioneered a new model of care that not only changed the course of the AIDS epidemic, but still serves as an example of the management of other chronic diseases.

Dr. Paul Volberding, professor of medicine at UCSF, was perhaps the leading clinician in the United States in the early days of the HIV epidemic. As a young oncologist finishing his training in the early 1980's, Volberding recalls seeing a young gay man with a previously rare tumor: Kaposi's sarcoma. Little did he know that the underlying immunodeficiency that led to KS would come to define his career. Volberding went on to become the founding chief of the AIDS division at San Francisco General Hospital, where he established the first inpatient AIDS wards and outpatient AIDS clinic. In this interview with Dr. Bob Wachter, chair of UCSF's Department of Medicine, Volberding recalls the early days, including the impact of activism and the fear that he and other clinicians would contract the illness. He also discusses the remarkable progress in turning HIV into a manageable chronic disease and the possibility of finding a cure for AIDS.  Series: "A Life in Medicine: People Shaping Healthcare Today" [Health and Medicine] [Business] [Show ID: 32873]

Dr. Paul Volberding, professor of medicine at UCSF, was perhaps the leading clinician in the United States in the early days of the HIV epidemic. As a young oncologist finishing his training in the early 1980's, Volberding recalls seeing a young gay man with a previously rare tumor: Kaposi's sarcoma. Little did he know that the underlying immunodeficiency that led to KS would come to define his career. Volberding went on to become the founding chief of the AIDS division at San Francisco General Hospital, where he established the first inpatient AIDS wards and outpatient AIDS clinic. In this interview with Dr. Bob Wachter, chair of UCSF's Department of Medicine, Volberding recalls the early days, including the impact of activism and the fear that he and other clinicians would contract the illness. He also discusses the remarkable progress in turning HIV into a manageable chronic disease and the possibility of finding a cure for AIDS.  Series: "A Life in Medicine: People Shaping Healthcare Today" [Health and Medicine] [Business] [Show ID: 32873]

Dr. Paul Volberding, professor of medicine at UCSF, was perhaps the leading clinician in the United States in the early days of the HIV epidemic. As a young oncologist finishing his training in the early 1980's, Volberding recalls seeing a young gay man with a previously rare tumor: Kaposi's sarcoma. Little did he know that the underlying immunodeficiency that led to KS would come to define his career. Volberding went on to become the founding chief of the AIDS division at San Francisco General Hospital, where he established the first inpatient AIDS wards and outpatient AIDS clinic. In this interview with Dr. Bob Wachter, chair of UCSF's Department of Medicine, Volberding recalls the early days, including the impact of activism and the fear that he and other clinicians would contract the illness. He also discusses the remarkable progress in turning HIV into a manageable chronic disease and the possibility of finding a cure for AIDS.  Series: "A Life in Medicine: People Shaping Healthcare Today" [Health and Medicine] [Business] [Show ID: 32873]

Dr. Paul Volberding, professor of medicine at UCSF, was perhaps the leading clinician in the United States in the early days of the HIV epidemic. As a young oncologist finishing his training in the early 1980's, Volberding recalls seeing a young gay man with a previously rare tumor: Kaposi's sarcoma. Little did he know that the underlying immunodeficiency that led to KS would come to define his career. Volberding went on to become the founding chief of the AIDS division at San Francisco General Hospital, where he established the first inpatient AIDS wards and outpatient AIDS clinic. In this interview with Dr. Bob Wachter, chair of UCSF's Department of Medicine, Volberding recalls the early days, including the impact of activism and the fear that he and other clinicians would contract the illness. He also discusses the remarkable progress in turning HIV into a manageable chronic disease and the possibility of finding a cure for AIDS.  Series: "A Life in Medicine: People Shaping Healthcare Today" [Health and Medicine] [Business] [Show ID: 32873]

Explore the current state of global HIV/AIDS. Panelists discuss what progress has been made in fighting this global epidemic, how research findings are being translated into improved clinical outcomes, and how the Bay Area research community is working to address the questions that remain. Panelists: Eran Bendavid, Assistant Professor, Medicine, Stanford; Stefano Bertozzi, Dean, School of Public Health, UC Berkeley; Diane Havlir, Professor and Chief of the HIV/AIDS Division & Positive Health Program, UCSF; Michael Larimore, Dean, School of Veterinary Medicine, UC Davis. Paul Volberding, Director, AIDS Research Institute and Director of Research, Global Health Sciences, UCSF, moderates. Series: "UC Global Health Institute" [Health and Medicine] [Professional Medical Education] [Show ID: 27756]

Explore the current state of global HIV/AIDS. Panelists discuss what progress has been made in fighting this global epidemic, how research findings are being translated into improved clinical outcomes, and how the Bay Area research community is working to address the questions that remain. Panelists: Eran Bendavid, Assistant Professor, Medicine, Stanford; Stefano Bertozzi, Dean, School of Public Health, UC Berkeley; Diane Havlir, Professor and Chief of the HIV/AIDS Division & Positive Health Program, UCSF; Michael Larimore, Dean, School of Veterinary Medicine, UC Davis. Paul Volberding, Director, AIDS Research Institute and Director of Research, Global Health Sciences, UCSF, moderates. Series: "UC Global Health Institute" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 27756]

Explore the current state of global HIV/AIDS. Panelists discuss what progress has been made in fighting this global epidemic, how research findings are being translated into improved clinical outcomes, and how the Bay Area research community is working to address the questions that remain. Panelists: Eran Bendavid, Assistant Professor, Medicine, Stanford; Stefano Bertozzi, Dean, School of Public Health, UC Berkeley; Diane Havlir, Professor and Chief of the HIV/AIDS Division & Positive Health Program, UCSF; Michael Larimore, Dean, School of Veterinary Medicine, UC Davis. Paul Volberding, Director, AIDS Research Institute and Director of Research, Global Health Sciences, UCSF, moderates. Series: "UC Global Health Institute" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 27756]

Explore the current state of global HIV/AIDS. Panelists discuss what progress has been made in fighting this global epidemic, how research findings are being translated into improved clinical outcomes, and how the Bay Area research community is working to address the questions that remain. Panelists: Eran Bendavid, Assistant Professor, Medicine, Stanford; Stefano Bertozzi, Dean, School of Public Health, UC Berkeley; Diane Havlir, Professor and Chief of the HIV/AIDS Division & Positive Health Program, UCSF; Michael Larimore, Dean, School of Veterinary Medicine, UC Davis. Paul Volberding, Director, AIDS Research Institute and Director of Research, Global Health Sciences, UCSF, moderates. Series: "UC Global Health Institute" [Health and Medicine] [Professional Medical Education] [Show ID: 27756]